Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
University of Pennsylvania scientists Katalin Karikó and Drew Weissman to be honoured at June 7 symposium in New York City for their research that enabled Covid-19 vaccines
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
This action makes Veklury the first approved Covid-19 treatment for children less than 12 years of age
A Promising Innovative Medicine (PIM) designation is an early indication that leniolisib is a candidate for the MHRA's Early Access to Medicines Scheme
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
April 25th is commemorated as World Malaria Day
With one of the most diverse lung cancer development programs, Novartis is focused on investments to advance the science, drive treatment and make an impact on patients
Subscribe To Our Newsletter & Stay Updated
